涨疯了！大牛股9天涨近200%，紧急提醒

Core Viewpoint - The stock price of Shutaishen (300204.SZ) has surged over 300% in two months, reaching 31.80 CNY per share, with a market capitalization of 15.2 billion CNY, driven by positive clinical trial results and announcements [1][5]. Group 1: Stock Performance - On June 3, Shutaishen closed at a limit-up price of 31.80 CNY, surpassing the 30 CNY mark, with a total market value of 15.2 billion CNY [1]. - The stock price was approximately 7.5 CNY in early April, indicating a price increase of over 300% in just two months [1]. - The main upward trend began on May 20, with the stock rising from 11 CNY to 31.80 CNY, a cumulative increase of over 188% [1]. Group 2: Clinical Trial Announcements - On May 28, Shutaishen announced preliminary results of the STSA-1002 injection for ARDS, showing good safety and tolerability, which further fueled investor interest [5]. - On June 3, the company announced that the conditional listing application for STSP-0601 was accepted by the National Medical Products Administration, which is intended for rapid hemostasis in hemophilia patients [5]. Group 3: Research Reports and Market Sentiment - Following the stock price surge, Caixin Securities published two research reports on Shutaishen, both maintaining a "buy" rating and projecting revenues of 294 million CNY, 448 million CNY, and 1.096 billion CNY for 2025-2027 [7]. - The last research report prior to this was published in March 2022, indicating a significant gap in coverage [8]. Group 4: Industry Trends - The recent surge in Shutaishen's stock price is attributed to a broader trend in the innovative drug sector, driven by accelerated commercialization of domestic innovative drugs and significant licensing agreements [11]. - The upcoming ASCO annual meeting is expected to showcase over 70 research results from Chinese pharmaceutical companies, highlighting the global presence of domestic innovative drugs [11]. - Analysts believe that the innovative drug sector will continue to be a key investment theme, supported by favorable policies and market conditions [11].